IP Library › Granted Patent US 12,600,989
Granted Patent B2
US 12,600,989 · App. 18/248,967 · Granted Apr 14, 2026

Adeno-associated virus (AAV) vector and uses therefor

Inventor: Qiang Wang (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania
C12N15/86C12N2750/14143C12N2750/14152
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,600,989
App. No.
18/248,967
Granted
Apr 14, 2026
Kind
B2
Abstract

Provided herein are engineered nucleic acid sequences encoding AAVhu68 which provide improved yields of packaged AAVhu68 viral particles. Also provided is a packaging host cell comprising the engineered nucleotide sequence and methods of using same to product recombinant AAVhu68 vectors useful for gene delivery. Further provided are production cell supernatants comprising improved yields of recombinant AAV vectors having AAVhu68 capsids produced using the nucleotide sequences provided herein.

Claims (21)

1 . A production host cell for generating a recombinant adeno-associated virus (rAAV) having an AAVhu68 capsid comprising:

(a) a nucleic acid sequence of SEQ ID NO: 1 or a sequence at least 99% identical thereto encoding the AAVhu68 vp1 capsid protein operably linked to expression control sequences which direct expression of the AAVhu68 vp1 capsid protein in the host cell;

(b) a nucleic acid molecule for packaging into the AAVhu68 capsid, said nucleic acid molecule comprising at least one AAV inverted terminal repeat (ITR) and a non-AAV nucleic acid sequence encoding a gene product operably linked to sequences which direct expression of the product in a host cell; and

(c) sufficient AAV rep functions and helper functions to permit packaging of the nucleic acid molecule into the AAVhu68 capsid.

2 . The production host cell according to claim 1 , wherein the host cell further comprises a nucleic acid sequence of about nucleotide 607 to about nucleotide 2211 of SEQ ID NO: 1 or a sequence at least 99% identical thereto encoding the AAVhu68 vp3 of about amino acid 203 to about amino acid 736 of SEQ ID NO: 2.

3 . The production host cell according to claim 1 , wherein the host cell is a human cell line or an insect cell line.

4 . The production host cell according to claim 1 , wherein the host cells is a HEK293 cell, HuH-7 cell, BHK cell, or Vero cell.

5 . The production host cell according to claim 1 , wherein the helper functions are provided by adenovirus, baculovirus, or herpes simplex virus proteins.

6 . The production host cell according to claim 1 , wherein the AAV rep is from a different AAV.

7 . The production host cell according to claim 6 , wherein the AAV rep is from AAV2.

8 . The production host cell according to claim 1 , wherein the AAV rep coding sequence and cap genes are on the same nucleic acid molecule, wherein there is optionally a spacer between the rep sequence and cap gene.

9 . The production host cell according to claim 8 , wherein the spacer is SEQ ID NO: 9.

10 . The production host cell according to claim 1 , wherein the AAV rep is AAVhu68rep characterized by the amino acid sequence of SEQ ID NO: 6, or a functional fragment thereof.

11 . The production host cell according to claim 10 , wherein the AAV rep is encoded by the nucleic acid sequence of SEQ ID NO: 5.

12 . A suspension comprising production host cells according to claim 1 .

13 . The suspension according to claim 12 , wherein the helper functions are herpes simplex virus helper functions.

14 . The suspension according to claim 12 , wherein the helper functions are baculovirus helper functions.

15 . A cell culture comprising the production host cell according to claim 1 .

16 . The cell culture according to claim 15 , wherein helper functions are adenovirus helper functions.

17 . A substrate comprising an adherent cell line comprising the production host cell according to claim 1 .

18 . The suspension according to claim 12 , wherein the host cells can produce an amount of rAAVhu68 particles that is at least 20% higher than the amount produced by AAVhu68 of SEQ ID NO: 3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2023
From: WANG, QIANG
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 063380/0788 →
Continuity (2)
Provisional Application 63093275 · Oct 18, 2020
Related Publication 20230383313A1 · Nov 30, 2023
References Cited (81)
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5741683A · Zhou et al. · 1998 [cited by applicant]
US 6057152A · Samulski et al. · 2000 [cited by applicant]
US 6200560B1 · Couto et al. · 2001 [cited by applicant]
US 6204059B1 · Samulski et al. · 2001 [cited by applicant]
US 6221349B1 · Couto et al. · 2001 [cited by applicant]
US 6268213B1 · Samulski et al. · 2001 [cited by applicant]
US 6491907B1 · Rabinowitz et al. · 2002 [cited by applicant]
US 6596535B1 · Carter · 2003 [cited by applicant]
US 6660514B1 · Zolotukhin et al. · 2003 [cited by applicant]
US 6951753B2 · Shenk et al. · 2005 [cited by applicant]
US 7094604B2 · Snyder et al. · 2006 [cited by applicant]
US 7125717B2 · Carter · 2006 [cited by applicant]
US 7172893B2 · Rabinowitz et al. · 2007 [cited by applicant]
US 7201898B2 · Monahan et al. · 2007 [cited by applicant]
US 7229823B2 · Samulski et al. · 2007 [cited by applicant]
US 7439065B2 · Ferrari et al. · 2008 [cited by applicant]
US 7442373B2 · Morrow et al. · 2008 [cited by applicant]
US 7456683B2 · Takano et al. · 2008 [cited by applicant]
US 7588772B2 · Kay et al. · 2009 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 10265417B2 · Wilson et al. · 2019 [cited by applicant]
US 10485883B2 · Wilson et al. · 2019 [cited by applicant]
US 10695441B2 · Wilson et al. · 2020 [cited by applicant]
US 10973928B2 · Wilson et al. · 2021 [cited by applicant]
US 11357867B2 · Wilson et al. · 2022 [cited by applicant]
US 11357868B2 · Wilson et al. · 2022 [cited by applicant]
US 20130045186A1 · Gao et al. · 2013 [cited by applicant]
US 20180243416A1 · Limberis · 2018 [cited by examiner]
US 20200056159A1 · Wilson et al. · 2020 [cited by applicant]
US 20200155704A1 · Wilson et al. · 2020 [cited by applicant]
WO WO2003042397 · 2003 [cited by applicant]
WO WO2005033321 · 2005 [cited by applicant]
WO WO2006110689 · 2006 [cited by applicant]
WO WO2011126808 · 2011 [cited by applicant]
WO WO2013049493 · 2013 [cited by applicant]
WO WO2017075119 · 2017 [cited by applicant]
WO WO2017160360 · 2017 [cited by applicant]
WO WO2018022608 · 2018 [cited by applicant]
WO WO2018160582 · 2018 [cited by applicant]
WO WO2019168961 · 2019 [cited by applicant]
WO WO2019169004 · 2019 [cited by applicant]
WO WO2019241535 · 2019 [cited by applicant]
WO WO2020132455 · 2020 [cited by applicant]
WO WO2021158915 · 2021 [cited by applicant]
WO WO2021165537 · 2021 [cited by applicant]
Buller et al., “Characterization of adenovirus-associated virus-induced polypeptides in KB cells,” J. Virol., Jan. 1978, vol. 25:331-338. [cited by applicant]
Buning et al., “Recent developments in adeno-associated virus vector technology,” J. Gene Med., May 2008, vol. 10:717-733. [cited by applicant]
Calcedo et al., “Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses,” Journal of Infectious Diseases, Feb. 2009, vol. 199(3)381-390. [cited by applicant]
Carter, “Handbook of Parvoviruses”, Tijsser (ed.), CRC Press, Jan. 1990, pp. 155-168. [cited by applicant]
Clement et al., “Manufacturing of recombinant adeno-associated viral vectors for clinical trials,” Mol Ther Methods Clin Dev, Mar. 2016, vol. 3:16002. [cited by applicant]
Fisher et al., “Transduction with Recombinant Adeno-Associated Virus for Gene Therapy is Limited by Leading-Strand Synthesis,” J. Virol., Jan. 1996, vol. 70:520-532. [cited by applicant]
Gao et al., “Adeno-associated viruses undergo substantial evolution in primates during natural infections,” PNAS, May 2003, vol. 100(10):6081-6086. [cited by applicant]
Gao et al., “Clades of Adeno-Associated Viruses are Widely Disseminated in Human Tissues,” J Virol, Jun. 2004, vol. 78(12):6381-6388. [cited by applicant]
Green and Sambrook (eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Jan. 2012, 2 pages, Cold Spring Harbor, NY. [cited by applicant]
Grieger & Samulski, “Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications,” Adv. Biochem. Engin/Biotechnol., Oct. 2005, vol. 99: 119-145. [cited by applicant]
Grimm et al., “Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2,” Gene therapy, Mar. 1999, vol. 6(7):1322-1330. [cited by applicant]
Lock et al., “Absolute Determination of Single-Stranded and Self-Complementary Adeno-Associated Viral Vector Genome Titers by Droplet Digital PCR,” Human Gene Therapy, Apr. 2014, vol. 25:115-125. [cited by applicant]
Lock et al., “Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale, ” Human Gene Therapy, Oct. 2010, vol. 21:1259-127. [cited by applicant]
McCarty et al., “Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis,” Gene Therapy, Aug. 2001, vol. 8(16):1248-1254. [cited by applicant]
Nei et al., “Neighbor Joining (NJI) Method,” Molecular Evolution and Phylogenetics, Jan. 2000, pp. 103-110, Oxford University Press, New York. [cited by applicant]
Povlich et al., “Particle Titer Determination and Characterization of rAAV Molecules Using Nanoparticle Tracking Analysis,” Molecular Therapy: AAV Vectors II, May 2016, vol. 24(S1):S122. [cited by applicant]
Rayaprolu et al., “Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics,” J Virol., Dec. 2013, vol. 87(24): 13150-13160. [cited by applicant]
Rose et al., “Structural proteins of adenovirus-associated viruses,” J. Virol., Nov. 1971, vol. 8:766-770. [cited by applicant]
Sambrook et al., “Molecular Cloning. A Laboratory Manual (2nd Ed.),” Jan. 1989, 2 pgs, Cold Spring Harbor Laboratory, New York. [cited by applicant]
Sawada-Hirai et al., “Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed,” J Immune Based Ther, Vaccines, May 2004, vol. 2:1-15. [cited by applicant]
Sofronescu, “Cerebrospinal Fluid Analysis,” Jun. 2022, 11 pages, accessed Sep. 13, 2023 at emedicine.medscape.com/article/2093316-overview. [cited by applicant]
Sommer et al., “Quantification of Adeno-Associated Virus Particles and Empty Capsids by Optical Density Measurement,” Molec. Ther., Jan. 2003, vol. 7:122-128. [cited by applicant]
Thomson et al., “A comprehensive comparison of multiple sequence alignments”, Nucl. Acids. Res., Jul. 1999, vol. 27(13):2682-2690. [cited by applicant]
UniProtKB, “P51608—MECP2_Human,” Oct. 1996, 10 pages, accessed Jul. 6, 2023 from https://www.uniprot.org/uniprotk/P51608/entry. [cited by applicant]
Wu et al., “Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose,” Molecular therapy: The Journal of the American Society of Gen… [cited by applicant]
Zanta-Boussif et al., “Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS,” Gene Therapy, Mar. 2009, vo… [cited by applicant]
International Search Report and Written Opinion issued on International Patent Application No. PCT/US2021/055436, dated Feb. 23, 2022. [cited by applicant]
U.S. Appl. No. 63/002,100, filed Mar. 30, 2020. [cited by applicant]
U.S. Appl. No. 63/027,731, filed May 20, 2020. [cited by applicant]
U.S. Appl. No. 63/023,593, filed May 12, 2020. [cited by applicant]
U.S. Appl. No. 63/043,562, filed Jun. 24, 2020. [cited by applicant]
U.S. Appl. No. 63/069,651, filed Aug. 24, 2020. [cited by applicant]
U.S. Appl. No. 63/079,290, filed Sep. 16, 2020. [cited by applicant]
U.S. Appl. No. 63/093,275, filed Oct. 18, 2020. [cited by applicant]
U.S. Appl. No. 63/038,488, filed Jun. 12, 2020. [cited by applicant]